AmeriPath chairman and CEO James New will retire on Feb. 1. Paul Queally, who is a director at the company, has been appointed chairman. A search for a new CEO will begin immediately, AmeriPath said.
In the meantime, the company will be run by the office of the CEO, including CFO David Redmond, president Joseph Sonnier, and COO Martin Stefanelli.
New has been the CEO of the company since AmeriPath was founded. Queally is also a general partner with Welsh Carson, Anderson & Stowe.
NeoGenomics has hired Thomas White as CEO. Michael Dent, former CEO, will continue as chairman, president, and chief medical officer. White most recently was president and CEO of SmartPill, a biotech company headquarted in Buffalo, NY. Prior to SmartPill, he was president and CEO of ConPharma Home Healthcare.
Richard Barker has been appointed executive chairman of the board at Molecular Staging. Barker has previously served as CEO of Chiron Diagnostics, and was general manager at IBM’s health care solutions business. He has also served for 13 years as the leader of McKinsey & Company’s European pharmaceutical practice.
James Meade has been named vice president of business development at Avalon Pharmaceuticals, and Paul Young has been promoted to vice president of research.
Meade comes to Avalon from Pfizer, where he helped to license anti-infective and urology products. He has also worked previously at Bayer, Chiron, and Cetus.
Young was most recently senior scientific director of discovery biology at Avalon, and a member of its scientific management committee. Prior to that, he worked as a senior scientist at Human Genome Sciences and Bayer and Genentech.
Nanostream has promoted Steve Hobbs to applications development director. Hobbs, who joined Nanostream in 2000 as a senior scientist, will be responsible for leading the development of new analytical applications for Nanostream’s Veloce micro parallel liquid chromatography product.
Prior to joining Nanostream, Hobbs was a senior scientist at Malinckrodt (now Tyco) where he developed new technologies for the company’s suite of gas analyzer- and tissue-spectroscopy products. He received a BA in chemistry from Berea College and a PhD in analytical chemistry from the University of North Carolina at Chapel Hill.
Spectral Diagnostics has appointed Ron Binns and Henry Friesen to its board of directors, bringing to eight the total number of board members. Binns is CFO of Nevada Capital. Friesen, meantime, has served as president of the Medical Research Council of Canada and is chairman of Genome Canada.
Genomics Collaborative has appointed Rick Episcopo as president, and John Boyce as senior director of business development. Both men are Sequenom alumns — Episcopo was executive VP of commercial operations, and Boyce was director of US sales.
In addition, Kevin Krenitsky, senior vice president and medical director, will become senior vice president of business development. Mike Pellini remains as CEO.